{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:09:58Z","timestamp":1792091398310,"version":"4.4.0"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T00:00:00Z","timestamp":1564704000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T00:00:00Z","timestamp":1564704000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s10741-019-09837-7","type":"journal-article","created":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T11:19:50Z","timestamp":1564744790000},"page":"367-380","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Angiotensin II and angiotensin 1\u20137: which is their role in atrial fibrillation?"],"prefix":"10.1007","volume":"25","author":[{"given":"Annamaria","family":"Mascolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konrad","family":"Urbanek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"De Angelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Sessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Scavone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liberato","family":"Berrino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Massimo Claudio","family":"Rosano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Capuano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,2]]},"reference":[{"key":"9837_CR1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2147\/CLEP.S47385","volume":"16","author":"M Zoni-Berisso","year":"2014","unstructured":"Zoni-Berisso M, Lercari F, Carazza T et al (2014) Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol 16:213\u2013220","journal-title":"Clin Epidemiol"},{"key":"9837_CR2","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","volume":"22","author":"PA Wolf","year":"1991","unstructured":"Wolf PA, Abbott RD, Kannel WB (1991) Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 22:983\u2013988","journal-title":"Stroke"},{"key":"9837_CR3","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0002-9343(99)80348-9","volume":"98","author":"AD Krahn","year":"1995","unstructured":"Krahn AD, Manfreda J, Tate RB, Mathewson FAL, Cuddy TE (1995) The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba follow-up study. Am J Med 98:476\u2013484","journal-title":"Am J Med"},{"key":"9837_CR4","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1161\/01.CIR.98.10.946","volume":"98","author":"EJ Benjamin","year":"1998","unstructured":"Benjamin EJ, Wolf PA, D'Agostino RB et al (1998) Impact of atrial fibrillation on the risk of death: the Framingham heart study. Circulation 98:946\u2013952","journal-title":"Circulation"},{"key":"9837_CR5","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1001\/archinte.158.3.229","volume":"158","author":"PA Wolf","year":"1998","unstructured":"Wolf PA, Mitchell JB, Baker CS, Kannel WB, D'Agostino RB (1998) Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med 158:229\u2013234","journal-title":"Arch Intern Med"},{"key":"9837_CR6","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0002-9343(02)01236-6","volume":"113","author":"S Stewart","year":"2002","unstructured":"Stewart S, Hart CL, Hole DJ, McMurray JJV (2002) A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew\/Paisley study. Am J Med 113:359\u2013364","journal-title":"Am J Med"},{"key":"9837_CR7","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0002-9343(02)01253-6","volume":"113","author":"H Vidaillet","year":"2002","unstructured":"Vidaillet H, Granada JF, Po C et al (2002) A population-based study of mortality among patients with atrial fibrillation or flutter. Am J Med 113:365\u2013370","journal-title":"Am J Med"},{"key":"9837_CR8","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1093\/eurheartj\/ehm012","volume":"28","author":"Y Miyasaka","year":"2007","unstructured":"Miyasaka Y, Barnes ME, Petersen RC, Cha SS, Bailey KR, Gersh BJ, Casaclang-Verzosa G, Abhayaratna WP, Seward JB, Iwasaka T, Tsang TSM (2007) Risk of dementia in stroke-free patients diagnosed with atrial fibrillation: data from a community-based cohort. Eur Heart J 28:1962\u20131967","journal-title":"Eur Heart J"},{"key":"9837_CR9","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/archinte.166.7.719","volume":"166","author":"C Lafuente-Lafuente","year":"2006","unstructured":"Lafuente-Lafuente C, Mouly S, Long\u00e1s-Tejero MA, Mah\u00e9 I, Bergmann JF (2006) Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch Intern Med 166:719\u2013728","journal-title":"Arch Intern Med"},{"key":"9837_CR10","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1161\/CIRCEP.109.859116","volume":"3","author":"R Cappato","year":"2010","unstructured":"Cappato R, Calkins H, Chen SA, Davies W, Iesaka Y, Kalman J, Kim YH, Klein G, Natale A, Packer D, Skanes A, Ambrogi F, Biganzoli E (2010) Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol 3:32\u201338","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"9837_CR11","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/europace\/eun048","volume":"10","author":"A Ringborg","year":"2008","unstructured":"Ringborg A, Nieuwlaat R, Lindgren P, Jonsson B, Fidan D, Maggioni AP, Lopez-Sendon J, Stepinska J, Cokkinos DV, Crijns HJGM (2008) Costs of atrial fibrillation in five European countries: results from the Euro Heart Survey on atrial fibrillation. Europace 10:403\u2013411","journal-title":"Europace"},{"key":"9837_CR12","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.hrthm.2011.12.016","volume":"9","author":"H Calkins","year":"2012","unstructured":"Calkins H, Kuck KH, Cappato R et al (2012) Heart Rhythm Society Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. 2012 HRS\/EHRA\/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society. Heart Rhythm 9:632\u2013696.e21","journal-title":"Heart Rhythm"},{"key":"9837_CR13","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.cjca.2010.11.011","volume":"27","author":"A Verma","year":"2011","unstructured":"Verma A, Macle L, Cox J, Skanes AC, CCS Atrial Fibrillation Guidelines Committee (2011) CCS atrial fibrillation guidelines committee. Canadian cardiovascular society atrial fibrillation guidelines 2010: catheter ablation for atrial fibrillation\/atrial flutter. Can J Cardiol 27:60\u201366","journal-title":"Can J Cardiol"},{"key":"9837_CR14","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1093\/eurheartj\/ehq278","volume":"31","author":"AJ Camm","year":"2010","unstructured":"Camm AJ, Kirchhof P, Lip GY et al (2010) Guidelines for the management of atrial fibrillation: the Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J 31:2369\u20132429","journal-title":"Eur Heart J"},{"key":"9837_CR15","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.4022\/jafib.1503","volume":"9","author":"P Stirbys","year":"2016","unstructured":"Stirbys P (2016) Neuro-atriomyodegenerative origin of atrial fibrillation and superimposed conventional risk factors: continued search to configure the genuine etiology of \u201ceternal arrhythmia\u201d. J Atr Fibrillation 9:1503","journal-title":"J Atr Fibrillation"},{"key":"9837_CR16","first-page":"972","volume":"6","author":"GM Nair","year":"2014","unstructured":"Nair GM, Nery PB, Redpath CJ et al (2014) The role of renin angiotensin system in atrial fibrillation. J Atrial Fibrillation 6:972","journal-title":"J Atrial Fibrillation"},{"key":"9837_CR17","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1080\/21623945.2015.1131881","volume":"5","author":"VB Patel","year":"2016","unstructured":"Patel VB, Basu R, Oudit GY (2016) ACE2\/Ang 1-7 axis: a critical regulator of epicardial adipose tissue inflammation and cardiac dysfunction in obesity. Adipocyte 5:306\u2013311","journal-title":"Adipocyte"},{"key":"9837_CR18","first-page":"1294","volume":"38","author":"CX Wong","year":"2017","unstructured":"Wong CX, Ganesan AN, Selvanayagam JB (2017) Epicardial fat and atrial fibrillation: current evidence, potential mechanisms, clinical implications, and future directions. Eur Heart J 38:1294\u20131302","journal-title":"Eur Heart J"},{"key":"9837_CR19","first-page":"e941","volume":"125","author":"M Rienstra","year":"2012","unstructured":"Rienstra M, McManus DD, Benjamin EJ (2012) Novel risk factors for atrial fibrillation: useful for risk prediction and clinical decision-making? Circulation 125:e941\u2013e946","journal-title":"Circulation"},{"key":"9837_CR20","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/cvr\/cvu045","volume":"102","author":"SN Hatem","year":"2014","unstructured":"Hatem SN, Sanders P (2014) Epicardial adipose tissue and atrial fibrillation. Cardiovasc Res 102:205\u2013213","journal-title":"Cardiovasc Res"},{"key":"9837_CR21","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejcts.2010.05.006","volume":"39","author":"A Kourliouros","year":"2011","unstructured":"Kourliouros A, Karastergiou K, Nowell J, Gukop P, Tavakkoli Hosseini M, Valencia O, Mohamed Ali V, Jahangiri M (2011) Protective effect of epicardial adiponectin on atrial fibrillation following cardiac surgery. Eur J Cardiothorac Surg 39:228\u2013232","journal-title":"Eur J Cardiothorac Surg"},{"key":"9837_CR22","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1093\/europace\/eur402","volume":"14","author":"MD Smit","year":"2012","unstructured":"Smit MD, Maass AH, De Jong AM et al (2012) Role of inflammation in early atrial fibrillation recurrence. Europace 14:810\u2013817","journal-title":"Europace"},{"key":"9837_CR23","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.ahj.2004.01.026","volume":"148","author":"DS Conway","year":"2004","unstructured":"Conway DS, Buggins P, Hughes E et al (2004) Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation. Am Heart J 148:462\u2013466","journal-title":"Am Heart J"},{"key":"9837_CR24","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ijcard.2006.08.061","volume":"121","author":"AE Malavazos","year":"2007","unstructured":"Malavazos AE, Ermetici F, Coman C, Corsi MM, Morricone L, Ambrosi B (2007) Influence of epicardial adipose tissue and adipocytokine levels on cardiac abnormalities in visceral obesity. Int J Cardiol 121:132\u2013134","journal-title":"Int J Cardiol"},{"key":"9837_CR25","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/eurheartj\/eht099","volume":"36","author":"N Venteclef","year":"2015","unstructured":"Venteclef N, Guglielmi V, Balse E et al (2015) Human epicardial adipose tissue induces fibrosis of the atrial myocardium through the secretion of adipo-fibrokines. Eur Heart J 36:795\u2013805a","journal-title":"Eur Heart J"},{"key":"9837_CR26","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S0735-1097(03)00578-3","volume":"42","author":"C Boixel","year":"2003","unstructured":"Boixel C, Fontaine V, Rucker-Martin C et al (2003) Fibrosis of the left atria during progression of heart failure is associated with increased matrix metalloproteinases in the rat. J Am Coll Cardiol 42:336\u2013344","journal-title":"J Am Coll Cardiol"},{"key":"9837_CR27","doi-asserted-by":"crossref","first-page":"E32","DOI":"10.1161\/hh1801.097644","volume":"89","author":"CA Carnes","year":"2001","unstructured":"Carnes CA, Chung MK, Nakayama T, Nakayama H, Baliga RS, Piao S, Kanderian A, Pavia S, Hamlin RL, McCarthy P, Bauer JA, van Wagoner D (2001) Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation. Circ Res 89:E32\u2013E38","journal-title":"Circ Res"},{"key":"9837_CR28","doi-asserted-by":"crossref","first-page":"6184","DOI":"10.3390\/ijms15046184","volume":"15","author":"UJ Jung","year":"2014","unstructured":"Jung UJ, Choi MS (2014) Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci 15:6184\u20136223","journal-title":"Int J Mol Sci"},{"key":"9837_CR29","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1161\/CIRCEP.112.971200","volume":"5","author":"K Nagashima","year":"2012","unstructured":"Nagashima K, Okumura Y, Watanabe I, Nakai T, Ohkubo K, Kofune M, Mano H, Sonoda K, Hiro T, Nikaido M, Hirayama A (2012) Does location of epicardial adipose tissue correspond to endocardial high dominant frequency or complex fractionated atrial electrogram sites during atrial fibrillation? Circ Arrhythm Electrophysiol 5:676\u2013683","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"9837_CR30","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.hrthm.2014.04.040","volume":"11","author":"S Nakahara","year":"2014","unstructured":"Nakahara S, Hori Y, Kobayashi S, Sakai Y, Taguchi I, Takayanagi K, Nagashima K, Sonoda K, Kogawa R, Sasaki N, Watanabe I, Okumura Y (2014) Epicardial adipose tissue-based defragmentation approach to persistent atrial fibrillation: its impact on complex fractionated electrograms and ablation outcome. Heart Rhythm 11:1343\u20131351","journal-title":"Heart Rhythm"},{"key":"9837_CR31","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1056\/NEJM199809033391003","volume":"339","author":"M Ha\u00efssaguerre","year":"1998","unstructured":"Ha\u00efssaguerre M, Ja\u00efs P, Shah DC, Takahashi A, Hocini M, Quiniou G, Garrigue S, le Mouroux A, le M\u00e9tayer P, Cl\u00e9menty J (1998) Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 339:659\u2013666","journal-title":"N Engl J Med"},{"key":"9837_CR32","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/nrendo.2015.6","volume":"11","author":"CA Romero","year":"2015","unstructured":"Romero CA, Orias M, Weir MR (2015) Novel RAAS agonists and antagonists: clinical applications and controversies. Nat Rev Endocrinol 11:242\u2013252","journal-title":"Nat Rev Endocrinol"},{"key":"9837_CR33","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ijcard.2016.03.085","volume":"226","author":"V Mollace","year":"2017","unstructured":"Mollace V, Gliozzi M, Capuano A, Rossi F (2017) Modulation of RAAS-natriuretic peptides in the treatment of HF: old guys and newcomers. Int J Cardiol 226:126\u2013131","journal-title":"Int J Cardiol"},{"key":"9837_CR34","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ijcard.2016.03.080","volume":"226","author":"F Rossi","year":"2017","unstructured":"Rossi F, Mascolo A, Mollace V (2017) The pathophysiological role of natriuretic peptide-RAAS cross talk in heart failure. Int J Cardiol 226:121\u2013125","journal-title":"Int J Cardiol"},{"key":"9837_CR35","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s40292-015-0120-5","volume":"22","author":"C Borghi","year":"2015","unstructured":"Borghi C, SIIA Task Force, Rossi F, SIF Task Force (2015) Role of the renin-angiotensin-aldosterone system and its pharmacological inhibitors in cardiovascular diseases: complex and critical issues. High Blood Press Cardiovasc Prev 22:429\u2013444","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"9837_CR36","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1042\/CS20100432","volume":"120","author":"G Nguyen","year":"2011","unstructured":"Nguyen G (2011) Renin, (pro)renin and receptor: an update. Clin Sci (Lond) 120:169\u2013178","journal-title":"Clin Sci (Lond)"},{"key":"9837_CR37","doi-asserted-by":"crossref","first-page":"3A","DOI":"10.1016\/S0002-9149(01)02321-9","volume":"89","author":"T Unger","year":"2002","unstructured":"Unger T (2002) The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol 89:3A\u20139A","journal-title":"Am J Cardiol"},{"key":"9837_CR38","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s11906-014-0429-9","volume":"16","author":"S Ahmad","year":"2014","unstructured":"Ahmad S, Varagic J, Groban L, Dell\u2019Italia LJ, Nagata S, Kon ND, Ferrario CM (2014) Angiotensin-(1\u201312): a Chymase-mediated cellular angiotensin II substrate. Curr Hypertens Rep 16:429","journal-title":"Curr Hypertens Rep"},{"key":"9837_CR39","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/S0735-1097(01)01170-6","volume":"37","author":"J Fielitz","year":"2001","unstructured":"Fielitz J, Hein S, Mitrovic V, Pregla R, Zurbr\u00fcgg HR, Warnecke C, Schaper J, Fleck E, Regitz-Zagrosek V (2001) Activation of the cardiac renin-angiotensin system and increased myocardial collagen expression in human aortic valve disease. J Am Coll Cardiol 37:1443\u20131449","journal-title":"J Am Coll Cardiol"},{"key":"9837_CR40","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1365-2125.2008.03234.x","volume":"66","author":"G Novo","year":"2008","unstructured":"Novo G, Guttilla D, Fazio G, Cooper D, Novo S (2008) The role of the renin\u2013angiotensin system in atrial fibrillation and the therapeutic effects of ACE-is and ARBS. Br J Clin Pharmacol 66:345\u2013351","journal-title":"Br J Clin Pharmacol"},{"key":"9837_CR41","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1161\/hc4601.099402","volume":"104","author":"D Li","year":"2001","unstructured":"Li D, Shinagawa K, Pang L, Leung TK, Cardin S, Wang Z, Nattel S (2001) Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 104:2608\u20132614","journal-title":"Circulation"},{"key":"9837_CR42","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.tips.2008.05.003","volume":"29","author":"C Marchesi","year":"2008","unstructured":"Marchesi C, Paradis P, Schiffrin EL (2008) Role of the renin-angiotensin system in vascular inflammation. Trends Pharmacol Sci 29:367\u2013374","journal-title":"Trends Pharmacol Sci"},{"key":"9837_CR43","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/sj.jhh.1002101","volume":"21","author":"P Dandona","year":"2007","unstructured":"Dandona P, Dhindsa S, Ghanim H, Chaudhuri A (2007) Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. J Hum Hypertens 21:20\u201327","journal-title":"J Hum Hypertens"},{"key":"9837_CR44","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.jacc.2003.07.014","volume":"42","author":"A Boldt","year":"2003","unstructured":"Boldt A, Wetzel U, Weigl J, Garbade J, Lauschke J, Hindricks G, Kottkamp H, Gummert JF, Dhein S (2003) Expression of angiotensin II receptors in human left andright atrial tissue in atrial fibrillation with and without underlying mitral valve disease. J Am Coll Cardiol 42:1785\u20131792","journal-title":"J Am Coll Cardiol"},{"key":"9837_CR45","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1161\/CIRCULATIONAHA.104.530592","volume":"113","author":"DP Zankov","year":"2006","unstructured":"Zankov DP, Omatsu-Kanbe M, Isono T, Toyoda F, Ding WG, Matsuura H, Horie M (2006) Angiotensin II potentiates the slow component of delayed rectifier K+ current via the AT1 receptor in guinea pig atrial myocytes. Circulation 113:1278\u20131286","journal-title":"Circulation"},{"key":"9837_CR46","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1016\/j.jnutbio.2013.07.002","volume":"24","author":"ME Frigolet","year":"2013","unstructured":"Frigolet ME, Torres N, Tovar AR (2013) The renin-angiotensin system in adipose tissue and its metabolic consequences during obesity. J Nutr Biochem 24:2003\u20132015","journal-title":"J Nutr Biochem"},{"key":"9837_CR47","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/ki.2010.391","volume":"79","author":"L Yvan-Charvet","year":"2011","unstructured":"Yvan-Charvet L, Quignard-Boulang\u00e9 A (2011) Role of adipose tissue renin-angiotensin system in metabolic and inflammatory diseases associated with obesity. Kidney Int 79:162\u2013168","journal-title":"Kidney Int"},{"key":"9837_CR48","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1161\/ATVBAHA.111.237198","volume":"31","author":"S Yamamoto","year":"2011","unstructured":"Yamamoto S, Yancey PG, Zuo Y, Ma LJ, Kaseda R, Fogo AB, Ichikawa I, Linton MRF, Fazio S, Kon V (2011) Macrophage polarization by angiotensin II-type 1 receptor aggravates renal injury-acceleration of atherosclerosis. Arterioscler Thromb Vasc Biol 31:2856\u20132864","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"9837_CR49","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.ijcard.2016.10.069","volume":"227","author":"A Mascolo","year":"2017","unstructured":"Mascolo A, Sessa M, Scavone C, de Angelis A, Vitale C, Berrino L, Rossi F, Rosano G, Capuano A (2017) New and old roles of the peripheral and brain renin-angiotensin-aldosterone system (RAAS): focus on cardiovascular and neurological diseases. Int J Cardiol 227:734\u2013742","journal-title":"Int J Cardiol"},{"issue":"2","key":"9837_CR50","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/JOE-12-0341","volume":"216","author":"Robson A S Santos","year":"2012","unstructured":"Santos RA, Ferreira AJ, Verano-Braga T, Bader M (2013) Angiotensin-converting enzyme 2, angiotensin-(1-7) and mas: new players of the renin-angiotensin system. J Endocrinol 216:R1\u2013R17","journal-title":"Journal of Endocrinology"},{"key":"9837_CR51","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ijcard.2009.07.015","volume":"146","author":"E Liu","year":"2011","unstructured":"Liu E, Xu Z, Li J, Yang S, Yang W, Li G (2011) Enalapril, irbesartan, and angiotensin-(1-7) prevent atrial tachycardia-induced ionic remodeling. Int J Cardiol 146:364\u2013370","journal-title":"Int J Cardiol"},{"key":"9837_CR52","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.regpep.2009.12.020","volume":"162","author":"E Liu","year":"2010","unstructured":"Liu E, Yang S, Xu Z, Li J, Yang W, Li G (2010) Angiotensin-(1-7) prevents atrial fibrosis and atrial fibrillation in long-term atrial tachycardia dogs. Regul Pept 162:73\u201378","journal-title":"Regul Pept"},{"key":"9837_CR53","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1002\/jcp.22940","volume":"227","author":"LL Souza","year":"2012","unstructured":"Souza LL, Costa-Neto CM (2012) Angiotensin-(1\u20137) decreases LPS-induced inflammatory response in macrophages. J Cell Physiol 227:2117\u20132122","journal-title":"J Cell Physiol"},{"key":"9837_CR54","doi-asserted-by":"crossref","first-page":"78726","DOI":"10.18632\/oncotarget.20221","volume":"8","author":"T Zhou","year":"2017","unstructured":"Zhou T, Han Z, Gu J, Chen S, Fan Y, Zhang H, Yin Y, Zhang J, Wang C (2017) Angiotensin-converting enzyme-2 overexpression improves atrial electrical remodeling through TRPM7 signaling pathway. Oncotarget 8:78726\u201378733","journal-title":"Oncotarget"},{"key":"9837_CR55","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2337\/db15-0399","volume":"65","author":"VB Patel","year":"2015","unstructured":"Patel VB, Mori J, McLean BA et al (2015) ACE2 deficiency worsens epicardial adipose tissue inflammation and cardiac dysfunction in response to diet-induced obesity. Diabetes 65:85\u201395","journal-title":"Diabetes"},{"key":"9837_CR56","doi-asserted-by":"crossref","first-page":"2D","DOI":"10.1016\/S0002-9149(02)03373-8","volume":"91","author":"WH Maisel","year":"2003","unstructured":"Maisel WH, Stevenson LW (2003) Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 91:2D\u20138D","journal-title":"Am J Cardiol"},{"key":"9837_CR57","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1161\/CIRCHEARTFAILURE.114.001276","volume":"7","author":"A Rossi","year":"2014","unstructured":"Rossi A, Gheorghiade M, Triposkiadis F, Solomon SD, Pieske B, Butler J (2014) Left atrium in heart failure with preserved ejection fraction: structure, function, and significance. Circ Heart Fail 7:1042\u20131049","journal-title":"Circ Heart Fail"},{"key":"9837_CR58","doi-asserted-by":"crossref","first-page":"e005277","DOI":"10.1161\/CIRCIMAGING.116.005277","volume":"9","author":"F Duca","year":"2016","unstructured":"Duca F, Kammerlander AA, Zotter-Tufaro C et al (2016) Interstitial fibrosis, functional status, and outcomes in heart failure with preserved ejection fraction: insights from a prospective cardiac magnetic resonance imaging study. Circ Cardiovasc Imaging 9:e005277","journal-title":"Circ Cardiovasc Imaging"},{"key":"9837_CR59","doi-asserted-by":"crossref","first-page":"e007849","DOI":"10.1161\/JAHA.117.007849","volume":"7","author":"F Shahid","year":"2018","unstructured":"Shahid F, Lip GYH, Shantsila E (2018) Role of monocytes in heart failure and atrial fibrillation. J Am Heart Assoc 7:e007849","journal-title":"J Am Heart Assoc"},{"key":"9837_CR60","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/cei.12612","volume":"181","author":"M Rutkowska-Zapa\u0142a","year":"2015","unstructured":"Rutkowska-Zapa\u0142a M, Suski M, Szatanek R, Lenart M, W\u0119glarczyk K, Olszanecki R, Grodzicki T, Strach M, G\u0105sowski J, Siedlar M (2015) Human monocyte subsets exhibit divergent angiotensin I-converting activity. Clin Exp Immunol 181:126\u2013132","journal-title":"Clin Exp Immunol"},{"key":"9837_CR61","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/j.peptides.2011.09.015","volume":"32","author":"H Yang","year":"2011","unstructured":"Yang H, Zeng XJ, Wang HX, Zhang LK, Dong XL, Guo S, du J, Li HH, Tang CS (2011) Angiotensin IV protects against angiotensin II-induced cardiac injury via AT4 receptor. Peptides 32:2108\u20132115","journal-title":"Peptides"},{"key":"9837_CR62","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ijcard.2012.02.009","volume":"165","author":"R Khatib","year":"2013","unstructured":"Khatib R, Joseph P, Briel M, Yusuf S, Healey J (2013) Blockade of the renin-angiotensin-aldosterone system (RAAS) for primary prevention of non-valvular atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials. Int J Cardiol 165:17\u201324","journal-title":"Int J Cardiol"},{"key":"9837_CR63","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1161\/01.CIR.100.4.376","volume":"100","author":"OD Pedersen","year":"1999","unstructured":"Pedersen OD, Bagger H, Kober L et al (1999) Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 100:376\u2013380","journal-title":"Circulation"},{"key":"9837_CR64","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0140-6736(98)05012-0","volume":"20","author":"L Hansson","year":"1999","unstructured":"Hansson L, Lindholm LH, Niskanen L et al (1999) Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP) randomised trial. Lancet 20:611\u2013616","journal-title":"Lancet"},{"key":"9837_CR65","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/S0140-6736(99)10327-1","volume":"20","author":"L Hansson","year":"1999","unstructured":"Hansson L, Lindholm LH, Ekbom T et al (1999) Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 20:1751\u20131756","journal-title":"Lancet"},{"key":"9837_CR66","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1136\/heart.86.5.527","volume":"86","author":"F Pizzetti","year":"2001","unstructured":"Pizzetti F, Turazza FM, Franzosi MG, Barlera S, Ledda A, Maggioni AP, Santoro L, Tognoni G, GISSI-3 Investigators (2001) GISSI-3 investigators. Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: the GISSI-3 data. Heart 86:527\u2013532","journal-title":"Heart"},{"key":"9837_CR67","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1161\/01.CIR.0000072793.81076.D4","volume":"107","author":"E Vermes","year":"2003","unstructured":"Vermes E, Tardif JC, Bourassa MG, Racine N, Levesque S, White M, Guerra PG, Ducharme A (2003) Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies of Left Ventricular Dysfunction (SOLVD) Trials. Circulation 107:2926\u20132931","journal-title":"Circulation"},{"key":"9837_CR68","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ahj.2004.09.033","volume":"149","author":"AP Maggioni","year":"2005","unstructured":"Maggioni AP, Latini R, Carson PE, Singh SN, Barlera S, Glazer R, Masson S, Cer\u00e8 E, Tognoni G, Cohn JN (2005) Val-HeFT investigators. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 149:548\u2013545","journal-title":"Am Heart J"},{"key":"9837_CR69","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jacc.2004.10.068","volume":"45","author":"K Wachtell","year":"2005","unstructured":"Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahl\u00f6f B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Devereux RB (2005) Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the losartan intervention for end point reduction in hypertension (LIFE) study. J Am Coll Cardiol 45:712\u2013719","journal-title":"J Am Coll Cardiol"},{"key":"9837_CR70","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ahj.2005.06.036","volume":"152","author":"A Ducharme","year":"2006","unstructured":"Ducharme A, Swedberg K, Pfeffer MA, Cohen-Solal A, Granger CB, Maggioni AP, Michelson EL, McMurray J, Olsson L, Rouleau JL, Young JB, Olofsson B, Puu M, Yusuf S, CHARM Investigators (2006) CHARM investigators. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program. Am Heart J 152:86\u201392","journal-title":"Am Heart J"},{"key":"9837_CR71","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.ahj.2007.04.062","volume":"54","author":"O Salehian","year":"2007","unstructured":"Salehian O, Healey J, Stambler B et al (2007) HOPE investigators. Impact of ramipril on the incidence of atrial fibrillation: results of the heart outcomes prevention evaluation study. Am Heart J 54:448\u2013453","journal-title":"Am Heart J"},{"key":"9837_CR72","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/HJH.0b013e3282f35c67","volume":"26","author":"RE Schmieder","year":"2008","unstructured":"Schmieder RE, Kjeldsen SE, Julius S et al (2008) VALUE trial group. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. J Hypertens 26:403\u2013411","journal-title":"J Hypertens"},{"key":"9837_CR73","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1097\/CCM.0b013e31825b8be2","volume":"40","author":"M Pretorius","year":"2012","unstructured":"Pretorius M, Murray KT, Yu C, Byrne JG, Billings FT IV, Petracek MR, Greelish JP, Hoff SJ, Ball SK, Mishra V, Body SC, Brown NJ (2012) Angiotensin-converting enzyme inhibition or mineralocorticoid receptor blockade do not affect prevalence of atrial fibrillation in patients undergoing cardiac surgery. Crit Care Med 40:2805\u20132812","journal-title":"Crit Care Med"},{"key":"9837_CR74","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1097\/HJH.0b013e3283522a51","volume":"30","author":"P Verdecchia","year":"2012","unstructured":"Verdecchia P, Dagenais G, Healey J et al (2012) Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint TrialTelmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease Investigators. Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial\/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease studies. J Hypertens 30:1004\u20131014","journal-title":"J Hypertens"},{"key":"9837_CR75","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS et al (2014) PARADIGM-HF investigators and committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993\u20131004","journal-title":"N Engl J Med"},{"key":"9837_CR76","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1161\/01.CIR.0000022665.18619.83","volume":"106","author":"AH Madrid","year":"2002","unstructured":"Madrid AH, Bueno MG, Rebollo JM et al (2002) Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 106:331\u2013336","journal-title":"Circulation"},{"key":"9837_CR77","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1016\/j.ehj.2003.08.014","volume":"24","author":"KC Ueng","year":"2003","unstructured":"Ueng KC, Tsai TP, Yu WC, Tsai CF, Lin MC, Chan KC, Chen CY, Wu DJ, Lin CS, Chen SA (2003) Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-lasting persistent atrial fibrillation: results of a prospective and controlled study. Eur Heart J 24:2090\u20132098","journal-title":"Eur Heart J"},{"key":"9837_CR78","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3317\/jraas.2004.027","volume":"5","author":"AH Madrid","year":"2004","unstructured":"Madrid AH, Mar\u00edn IM, Cervantes CE et al (2004) Prevention of recurrences in patients with lone atrial fibrillation. The dose-dependent effect of angiotensin II receptor blockers. J Renin Angiotensin Aldosterone Syst 5:114\u2013120","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"9837_CR79","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.hrthm.2004.08.008","volume":"1","author":"KT Murray","year":"2004","unstructured":"Murray KT, Rottman JN, Arbogast PG, Shemanski L, Primm RK, Campbell WB, Solomon AJ, Olgin JE, Wilson MJ, Dimarco JP, Beckman KJ, Dennish G, Naccarelli GV, Ray WA, AFFIRM Investigators (2004) AFFIRM investigators. Inhibition of angiotensin II signaling and recurrence of atrial fibrillation in AFFIRM. Heart Rhythm 1:669\u2013675","journal-title":"Heart Rhythm"},{"key":"9837_CR80","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1093\/eurheartj\/ehl190","volume":"27","author":"N Dagres","year":"2006","unstructured":"Dagres N, Karatasakis G, Panou F, Athanassopoulos G, Maounis T, Tsougos E, Kourea K, Malakos I, Kremastinos DT, Cokkinos DV (2006) Pre-treatment with irbesartan attenuates left atrial stunning after electrical cardioversion of atrial fibrillation. Eur Heart J 27:2062\u20132068","journal-title":"Eur Heart J"},{"key":"9837_CR81","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1093\/eurheartj\/ehl135","volume":"27","author":"Y Yin","year":"2006","unstructured":"Yin Y, Dalal D, Liu Z, Wu J, Liu D, Lan X, Dai Y, Su L, Ling Z, She Q, Luo K, Woo K, Dong J (2006) Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation. Eur Heart J 27:1841\u20131847","journal-title":"Eur Heart J"},{"key":"9837_CR82","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/01.fjc.0000193808.99773.28","volume":"47","author":"R Fogari","year":"2006","unstructured":"Fogari R, Mugellini A, Destro M, Corradi L, Zoppi A, Fogari E, Rinaldi A (2006) Losartan and prevention of atrial fibrillation recurrence in hypertensive patients. J Cardiovasc Pharmacol 47:46\u201350","journal-title":"J Cardiovasc Pharmacol"},{"key":"9837_CR83","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/ajh.2008.217","volume":"21","author":"R Fogari","year":"2008","unstructured":"Fogari R, Derosa G, Ferrari I, Corradi L, Zoppi A, Lazzari P, Santoro T, Preti P, Mugellini A (2008) Effect of valsartan and ramipril on atrial fibrillation recurrence and P-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation. Am J Hypertens 21:1034\u20131039","journal-title":"Am J Hypertens"},{"key":"9837_CR84","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0828-282X(08)70670-6","volume":"24","author":"M Palardy","year":"2008","unstructured":"Palardy M, Ducharme A, Nattel S, Tardif JC, White M, Racine N, T\u00e9treault K, Dabouz F, Talajic M, Roy D, CTAF Investigators (2008) CTAF investigators. Absence of protective effect of renin-angiotensin system inhibitors on atrial fibrillation development: insights from the Canadian trial of atrial fibrillation (CTAF). Can J Cardiol 24:709\u2013713","journal-title":"Can J Cardiol"},{"key":"9837_CR85","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1056\/NEJMoa0805710","volume":"360","author":"M Disertori","year":"2009","unstructured":"Disertori M, Latini R, Barlera S et al (2009) GISSI-AF investigators. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 360:1606\u20131617","journal-title":"N Engl J Med"},{"key":"9837_CR86","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jacc.2008.08.071","volume":"53","author":"F Belluzzi","year":"2009","unstructured":"Belluzzi F, Sernesi L, Preti P, Salinaro F, Fonte ML, Perlini S (2009) Prevention of recurrent lone atrial fibrillation by the angiotensin-II converting enzyme inhibitor ramipril in normotensive patients. J Am Coll Cardiol 53:24\u201329","journal-title":"J Am Coll Cardiol"},{"key":"9837_CR87","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.athoracsur.2010.11.063","volume":"91","author":"JG Wang","year":"2011","unstructured":"Wang JG, Li Y, Shi JH, Han J, Cui YQ, Luo TG, Meng X (2011) Treatment of long-lasting persistent atrial fibrillation using minimally invasive surgery combined with irbesartan. Ann Thorac Surg 91:1183\u20131189","journal-title":"Ann Thorac Surg"},{"key":"9837_CR88","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/europace\/euq439","volume":"13","author":"T Yamashita","year":"2011","unstructured":"Yamashita T, Inoue H, Okumura K, Kodama I, Aizawa Y, Atarashi H, Ohe T, Ohtsu H, Kato T, Kamakura S, Kumagai K, Kurachi Y, Koretsune Y, Saikawa T, Sakurai M, Sato T, Sugi K, Nakaya H, Hirai M, Hirayama A, Fukatani M, Mitamura H, Yamazaki T, Watanabe E, Ogawa S, on behalf of the J-RHYTHM II Investigators, Katoh T, Igawa O, Matsumoto N, Yamashita T, Kaneko Y, Watanabe E, Ogawa S, Osaka T, Fujii E, Niwano S, Yoshioka K, Kato M, Okazaki O, Kusano K, Okuyama Y, Furushima H, Suzuki M, Noda T, Kawara T, Sato T, Kamakura S, Endoh Y, Kumagai K, Hiyoshi Y, Ishiyama T, Ohtsuka T, Matsumoto M, Chishaki A, Shinohara T, Shirayama T, Koretsune Y, Yokoyama E, Ajiki K, Fujio K, Sugi K, Yamakawa T, Yusu S, Inoue H, Kawamura Y, Hayano M, Date T, Mizusawa Y, Kobayashi Y, Satomi K, Imai Y, Atarashi H, Fukunami M, Yokoshiki H, Betsuyaku T, Okumura K, Takeda H, Matsumoto K, Okishige K, Tagawa M, Hirai M, Okazaki H (2011) J-RHYTHM II investigators. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study). Europace 13:473\u2013479","journal-title":"Europace"},{"key":"9837_CR89","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1056\/NEJMoa1008816","volume":"364","author":"S Yusuf","year":"2011","unstructured":"Yusuf S, Healey JS, Pogue J et al (2011) ACTIVE I investigators. Irbesartan in patients with atrial fibrillation. N Engl J Med 364:928\u2013938","journal-title":"N Engl J Med"},{"key":"9837_CR90","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1177\/1470320312443909","volume":"13","author":"D Galzerano","year":"2012","unstructured":"Galzerano D, Di Michele S, Paolisso G et al (2012) A multicentre, randomized study of telmisartan versus carvedilol for prevention of atrialfibrillationrecurrence in hypertensivepatients. J ReninAngiotensin Aldosterone Syst 13:496\u2013503","journal-title":"J ReninAngiotensin Aldosterone Syst"},{"key":"9837_CR91","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1177\/1074248410395018","volume":"17","author":"R Fogari","year":"2012","unstructured":"Fogari R, Mugellini A, Zoppi A, Preti P, Destro M, Lazzari P, Derosa G (2012) Effect of telmisartan and ramipril on atrial fibrillation recurrence and severity in hypertensive patients with metabolic syndrome and recurrent symptomatic paroxysmal and persistent atrial fibrillation. J Cardiovasc Pharmacol Ther 17:34\u201343","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"9837_CR92","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1161\/CIRCEP.111.965178","volume":"5","author":"A Goette","year":"2012","unstructured":"Goette A, Sch\u00f6n N, Kirchhof P, Breithardt G, Fetsch T, H\u00e4usler KG, Klein HU, Steinbeck G, Wegscheider K, Meinertz T (2012) Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial. Circ Arrhythm Electrophysiol 5:43\u201351","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"9837_CR93","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0140-6736(00)02602-7","volume":"356","author":"JL Rouleau","year":"2000","unstructured":"Rouleau JL, Pfeffer MA, Stewart DJ, Isaac D, Sestier F, Kerut EK, Porter CB, Proulx G, Qian C, Block AJ (2000) Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 356:615\u2013620","journal-title":"Lancet"},{"key":"9837_CR94","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(97)01187-2","volume":"349","author":"B Pitt","year":"1997","unstructured":"Pitt B, Segal R, Martinez FA et al (1997) Randomised trial of losartan versus captopril in patients over 65 with heart failure (evaluation of losartan in the elderly study, ELITE). Lancet 349:747\u2013752","journal-title":"Lancet"},{"key":"9837_CR95","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1136\/heartjnl-2017-312573","volume":"104","author":"CY Huang","year":"2018","unstructured":"Huang CY, Yang YH, Lin LY, Tsai CT, Hwang JJ, Chen PC, Lin JL (2018) Renin-angiotensin-aldosterone blockade reduces atrial fibrillation in hypertrophic cardiomyopathy. Heart 104:1276\u20131283","journal-title":"Heart"},{"key":"9837_CR96","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1016\/j.jacc.2004.11.070","volume":"45","author":"JS Healey","year":"2005","unstructured":"Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S, Connolly SJ (2005) Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 45:1832\u20131839","journal-title":"J Am Coll Cardiol"},{"key":"9837_CR97","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/0091270005283284","volume":"46","author":"JS Kalus","year":"2006","unstructured":"Kalus JS, Coleman CI, White CM (2006) The impact of suppressing the renin-angiotensin system on atrial fibrillation. J Clin Pharmacol 46:21\u201328","journal-title":"J Clin Pharmacol"},{"key":"9837_CR98","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ahj.2006.01.007","volume":"152","author":"K Anand","year":"2006","unstructured":"Anand K, Mooss AN, Hee TT, Mohiuddin SM (2006) Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation. Am Heart J 152:217\u2013222","journal-title":"Am Heart J"},{"key":"9837_CR99","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ijcard.2012.02.009","volume":"165","author":"R Khatib","year":"2013","unstructured":"Khatib R, Joseph P, Briel M, Yusuf S, Healey J (2013) Blockade of the renin-angiotensin-aldosterone system (RAAS) for primary prevention of non-valvular atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials. Int J Cardiol 165:17\u201324","journal-title":"Int J Cardiol"},{"key":"9837_CR100","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s10557-011-6346-0","volume":"26","author":"M Disertori","year":"2012","unstructured":"Disertori M, Barlera S, Staszewsky L, Latini R, Quintarelli S, Franzosi MG (2012) Systematic review and meta-analysis: renin-angiotensin system inhibitors in the prevention of atrial fibrillation recurrences: an unfulfilled hope. Cardiovasc Drugs Ther 26:47\u201354","journal-title":"Cardiovasc Drugs Ther"},{"key":"9837_CR101","doi-asserted-by":"crossref","first-page":"475","DOI":"10.7555\/JBR.29.20140149","volume":"29","author":"D Zhao","year":"2015","unstructured":"Zhao D, Wang ZM, Wang LS (2015) Prevention of atrial fibrillation with renin-angiotensin system inhibitors on essential hypertensive patients: a meta-analysis of randomized controlled trials. J Biomed Res 29:475\u2013485","journal-title":"J Biomed Res"},{"issue":"4","key":"9837_CR102","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1177\/1074248415619490","volume":"21","author":"S Chaugai","year":"2016","unstructured":"Chaugai S, Meng WY, Ali SA (2016) Effects of RAAS blockers on atrial fibrillation prophylaxis: an updated systematic review and meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol Ther 21(4):388\u2013404","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"9837_CR103","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1042\/CS20120078","volume":"123","author":"JM Saavedra","year":"2012","unstructured":"Saavedra JM (2012) Angiotensin II AT(1) receptor blockers as treatments for inflammatory brain disorders. Clin Sci (Lond) 123:567\u2013590","journal-title":"Clin Sci (Lond)"},{"key":"9837_CR104","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1161\/01.CIR.101.22.2612","volume":"101","author":"H Nakashima","year":"2000","unstructured":"Nakashima H, Kumagai K, Urata H, Gondo N, Ideishi M, Arakawa K (2000) Angiotensin II antagonist prevents electrical remodelling in atrial fibrillation. Circulation. 101:2612\u20132617","journal-title":"Circulation."},{"key":"9837_CR105","doi-asserted-by":"crossref","first-page":"147032031875526","DOI":"10.1177\/1470320318755269","volume":"19","author":"X Wang","year":"2018","unstructured":"Wang X, Li G (2018) Irbesartan prevents sodium channel remodeling in a canine model of atrial fibrillation. J Renin-Angiotensin-Aldosterone Syst 19:1470320318755269","journal-title":"J Renin-Angiotensin-Aldosterone Syst"},{"key":"9837_CR106","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.amjhyper.2006.09.016","volume":"20","author":"Y Mori","year":"2007","unstructured":"Mori Y, Itoh Y, Tajima N (2007) Angiotensin II receptor blockers downsize adipocytes in spontaneously type 2 diabetic rats with visceral fat obesity. Am J Hypertens 20:431\u2013436","journal-title":"Am J Hypertens"},{"key":"9837_CR107","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/hr.2009.55","volume":"32","author":"M Iwai","year":"2009","unstructured":"Iwai M, Horiuchi M (2009) Role of renin-angiotensin system in adipose tissue dysfunction. Hypertens Res 32:425\u2013427","journal-title":"Hypertens Res"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-019-09837-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10741-019-09837-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-019-09837-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T19:50:24Z","timestamp":1695066624000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10741-019-09837-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,2]]},"references-count":107,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["9837"],"URL":"https:\/\/doi.org\/10.1007\/s10741-019-09837-7","relation":{},"ISSN":["1382-4147","1573-7322"],"issn-type":[{"value":"1382-4147","type":"print"},{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,2]]},"assertion":[{"value":"2 August 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}